Dr. Reddys Labs (RDY) Reports Q4 EPS of $0.07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Dr. Reddy’s Q4 and FY16 Financial Results
May 12, 2016 6:47 AM EDT
Q4 Revenues at Rs. 37.6 billion
(YoY decline of 3%)
Q4 EBITDA at Rs. 4.8 billion
(12.8% of the revenues)
Q4 Adjusted EBITDA* at Rs. 9.0 billion
(24.0% of the
revenues)
FY16 Revenues at Rs. 154.7 billion
(YoY growth of 4%)
FY16 EBITDA at Rs. 36.3 billion
(23.4% of the revenues)
FY16 Adjusted EBITDA* at Rs. 41.2 billion
(26.7% of the
revenues)
HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddys Laboratories Ltd. (NYSE: RDY | BSE: 500124 | NSE:... More
